A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
A Open-label, Multicenter Phase II Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative Advanced Breast Cancer
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A PHASE2 clinical study on HR-positive, HER2-negative Advanced Breast Cancer, this trial is actively recruiting participants. The trial is conducted by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and has accumulated 1 data snapshot since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
1 version recordedEligibility Summary
No eligibility information available.
Contact Information
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China, Changsha, China, Chongqing, China, Dalian, China, Guangzhou, China, Hangzhou, China, Harbin, China, Hefei, China, Lanzhou, China, Nanjing, China and 7 more location s